A common amino acid may calm sickle cell pain crises — a trial puts it to the test

NCT ID NCT02447874

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial tests whether giving extra arginine intravenously to children with sickle cell disease during a painful vaso-occlusive crisis can lower pain scores, reduce the need for painkillers, and shorten hospital or emergency department visits. The study enrolls children aged 7 to 21 with severe sickle cell disease who require opioid pain relief. Researchers will measure how the body processes arginine and whether it boosts nitric oxide production, which may improve blood flow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
arginine given intravenously
What this could lead to
If it works, this could offer a simple, safe way to ease severe pain and shorten hospital stays for children with sickle cell disease.
What could go wrong
This is an early-phase trial with only 21 participants, so results may not apply broadly. Arginine may not reduce pain or length of stay as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Healthcare fo Atlanta at Hughes Spalding

    RECRUITING

    Atlanta, Georgia, 30303, United States

  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital

    RECRUITING

    Atlanta, Georgia, 30329, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.